Metabolex, Inc.

Cymabay Therapeutics, Inc.

Nankai University

University of Limerick

Peng Cheng

Yan Zhu

Jingyuan Ma

Xin Chen

Jiangao Song

Imad Nashashibi

Alison Murphy

Jeffrey D Johnson

Christopher J Rabbat

Maria E Wilson

L Edward Clemens

Aaron Robert Novack

Dong Fang Shi

Francine M Gregoire

Vera Rakhmanova

Christoper J Rabbat

Michael Zaworotko

Wei Shi

Zhiqiang Wang

Xiu-Ping Yan

Cheng-Xiong Yang

Shi-Yuan Zhang

Jiangong Ma

Aaron Novack

A process method for producing a pesticide by using carbon dioxide includes: weighing a 1,3-cyclohexanedione substrate 1(a-e), a catalyst and CsCOin a Schlenk bottle, degassing, and continuously introducing 1 atm of carbon dioxide; adding a solvent and reacting for 48 h in an oil bath at 50&#xb0; C. After the reaction was completed, post-treatment was carried out to obtain a 2-carboxyl-1,3-cyclohexanedione compound 2(a-e). The obtained acid is acylated and then added dropwise to a dichloromethane solution containing aniline to react for 2 h at room temperature. After the reaction, column chromatography was performed to obtain a pesticide compound 3(a-e). Adding the pesticide compound 3(a-e) into 50% concentrated sulfuric acid and refluxing at 80&#xb0; C. for 8 hours. Through separation, a pesticide product compound 4(a-e) was obtained. The process method is simple, with low requirements on equipment, wide sources of raw materials, low cost, low toxicity and easy industrial scale-up production.

Process method for producing pesticide by using carbon dioxide

A porous chiral material of formula [M(L)(A)]Xwherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and Xis an anion.

Porous chiral materials and uses thereof

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.

Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.

N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

The present disclosure provides 2,4-disubstituted thiazoles of the general structure shown below that are agonists of G-protein coupled receptor (IC-GPCR2). Also, provided are compositions comprising these compounds as well as methods for using these compounds in a variety of applications including diabetes and metabolic disorders. 

2,4-disubsituted thiazoles and pharmaceutical compositions thereof

The present invention provides a compounds the formula (IV): and methods for producing an &#x3b1;-(phenoxy)phenylacetic acid compound of the formula: wherein Ris a member selected from the group consisting of: each Ris a member independently selected from the group consisting of (C-C)alkyl, halo, (C-C)haloalkyl, amino, (C-C)aminoalkyl, amido, (C-C)amidoalkyl, (C-C)sulfonylalkyl, (C-C)sulfamylalkyl, (C-C)alkoxy, (C-C)heteroalkyl, carboxy and nitro; the subscript n is 1 when Rhas the formula (a) or (b) and 2 when Rhas the formula (c) or (d); the subscript m is an integer of from 0 to 3; * indicates a carbon which is enriched in one stereoisomeric configuration; and the wavy line indicates the point of attachment of R; and compounds.

Process for the stereoselective preparation of (&#x2212;)-halofenate and derivatives thereof

Compounds, compositions, and methods relating to 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine or a pharmaceutically acceptable salt thereof are provided for the treatment of Type II diabetes and other diseases associated with poor glycemic control.

5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.

Modulators of PPAR and methods of their preparation

The present invention provides a methods and compounds for producing an enantiomerically enriched &#x3b1;-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where Ris alkyl or haloalkyl and X is halide.

Resolution of &#x3b1;-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

Growing community of inventors

Union City, CA, United States of America

Peng Cheng